NOVO NORDISK A S files 6-K

Novo Nordisk announced positive topline results from its Phase 3 HIBISCUS trial for etavopivat, a potential new treatment for sickle cell disease, showing a 27% reduction in vaso-occlusive crisis events and a superior hemoglobin response compared to placebo. The company plans to submit for the first regulatory approval of etavopivat in the second half of 2026.